|
|
||||||||||||||||||||||||||||||||||||||||||
| ricky.....FYI "In connection with the employment of its Chief Financial Officer, the Company granted Alan Gallantar options to purchase an aggregate of 4,547,880 shares of the Company's common stock. Such options have a term of ten years commencing October 1, 1999 through September 30, 2009 and have an exercise price of $0.24255 per share. These options are fully vested." |
| No
AVR118, yet. Weizmann re: benefit of garlic: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15056375 |
| sue
he wont sell his options he will hold them forever waiting and knowing
the true potential of advr like all us idiot longs have done i bet he
buys more (not)!!!! i just hope as he walks out the door hes not
laughing if you no what i mean. |
| i
remember many here saying WAIT TILL we get dr h. we get results for hpv we get results for topical we get pink eye results we get china and other patents we get rid of dr h. we get exposure at conferences we get argentina test results we get isreal test results we get financing we get the new boss we get rid of overpaid galanter we get that abstract exposure we got .117 after all that the new boss must be very impressive i bet big pharms are upset they didnt get her. theres no bs in this post and yes ill buy more it just seems strange that we have (a miracle drug) and after 20 years nobody in the world thinks so but us at rb. |
| "On
July 8, 2002, the Company extended an agreement with the Weizmann
Institute of Science and Yeda its developmental arm in Israel, to
conduct research on the effects of AVR118 on the immune system,
especially on T lymphocytes. In addition, scientists will explore the
effects of AVR118 in animal models. Under its provisions the study
period is extended for another twelve months to July 7, 2003. Total
costs incurred in connection with this research are expected to be
$138,000. Since inception, through December 31, 2003, the Company
expensed $120,000 and paid $90,000 in connection with this agreement.
Final payment has not been made pending receipt, review and approval of
the final report." Since we have not heard anything published yet from the Weizmann studies -- IS IT POSSIBLE, some sort of Abstract concerning "T lymphocytes" will be presented by the company at the ASCO conference? Perhaps, the company is going to make that final payment to Weizmann? Just some thoughts!!! |
| Larry
Pomerantz:: http://www.edgar-online.com/brand/yahoo/people/?last=POMERANTZ&first=LARRY&ftype=ALL |
|
||||||||||||||||||||||||||||||||||||||||||||||
| Try EDGAR Online Premium - free for two weeks! - click here. |
| HIV
in China WHO Director General Calls for Increased Attention to HIV in China Apr 21, 2004 World Health Organization Director-General Jong-Wook Lee on Tuesday during a lecture at the Beijing Union Medical College in China called on the Chinese government to pay more attention to tuberculosis and HIV/AIDS in the country, Xinhuanet/China View reports. During his two-day visit -- his first official visit to the country since assuming his position in July 2003 -- Lee also met with Chinese leaders and health officials (Xinhuanet/China View, 4/20). The Chinese government estimates that there are 840,000 HIV-positive people in the country and that 80,000 people have AIDS; however, some experts believe that those figures are underestimates. The United Nations estimates that there are at least one million HIV-positive people in China and that the number could grow to 20 million people by 2010 (Kaiser Daily HIV/AIDS Report, 4/15). Lee also was scheduled to meet with Chinese Premier Wen Jiabao to discuss China's role in WHO's 3 by 5 Initiative, which aims to provide antiretroviral drugs to three million HIV-positive people worldwide by 2005 (Agence France-Presse, 4/19). About 60,000 to 70,000 of the people treated in the program would be in China, according to Kyodo News (Kyodo News, 4/19). |
| anna
mny : Alan, the ex-CFO had loaned the company personal funds at a time
when it was almost bankrupt, to help keep operations going a month or
two. This had been recorded in an SEC filing. |
| "Answer
this question. Does "IT work?" ------------------------ Unfortunately ADVR has never been able to get ANY bona-fide testing trials to completion to answer your very basic question. |
| At
least be honest Tele.... Gallantar loaned the company some funds, short
term with interest, so the company could hurry up and pay Bregman and
Friedland their severance pay! The CEO & CFO couldn't wait to get rid of the founders ASAP. Bregman was actually evicted by Gallantar personally! That was the beginning of the "death spiral" of ADVR that got us in the position we are today created by all the "quality investor" financing Hirschman and Gallantar brought to the table since! Gallantar did very well with his salary and options in the realm of working for a tiny OTCBB startup with no revenues. Even EVEN will agree with that statement! - - - - - View Replies » |
| Anna
-- No, he has been working without a contract for 18 months and is part
of the old regime..... It was time for his departure...no big whoop. Unless something dramatic turns up (like filing false SEC docs), his departure is no big deal IMO. |
| tellslikeitis, Thank You. I take it the man has fallen ill or someone close has on the one hand but if he indeed loaned personal funds to keep Advanced Viral aflot, why the lack of celebratory accolades in the press release ? Just an observation. I think there is a lot of risk with Advanced Viral and potential large upside. Seems like the company as well as the board from what I read has been through very rough times. Has it been considered that this Mr K the Klown is an ex employee ? I have seen people who were let go, unleash such havoc. Its unfortunate but better on a forum board than at a company location. Thank You anna |
| It
was my understanding that there were multiple occasions when investors
wanted in and SZH vetoed the arrangement for various reasons - one of
which was that there was a personality clash. Now why would someone heading up a company in dire financial straits and struggling to stay afloat abandon an offer because of discrepancies of personalities?? Only at ADVR headquarters - and one of the reasons the company is trading so low now. |
| 2/25/04.
ADVR Granted a United States Patent for the Treatment of AIDS 25 February 2004, 08:14am ET YONKERS, N.Y., Feb. 25 /PRNewswire-FirstCall/ -- Advanced Viral Research Corp. (BB:ADVR) today announced that it was issued a United States patent (No. 6,696,422) for the treatment of HIV infections with AVR118 as a combination therapy with other HIV drugs. The Centers for Disease Control and Prevention (CDC) estimates that 850,000 to 950,000 United States residents are living with HIV infection, one-quarter of whom are unaware of their infection. Over 40,000 new patients are diagnosed with HIV infections each year in the United States -- about 70 percent among men and 30 percent among women. Of these newly infected people, half are younger than 25 years of age. "The issuance of this patent allows us to increase our intellectual property protection in an important therapeutic area," said Dr. Elma Hawkins, President and CEO of Advanced Viral Research Corp. "We previously announced that China granted the Company a similar patent for AVR118 in the treatment of HIV infections." ADVR's AVR118 represents a biopolymer that possesses novel immunomodulator activity. This peptide-nucleic acid, which to date has shown a very favorable safety profile, appears to stimulate the proinflammatory responses required to combat viral infections such as HIV and human papillomavirus and to dampen aberrant autoimmune-type inflammatory responses, such as occur in patients with rheumatoid arthritis. AVR118 is in clinical trials in Israel for the treatment of cachexia (body wasting) in patients with AIDS. Mentioned Last Change ADVR 0.11 0.01dollars or (8.33%) For further information regarding Advanced Viral Research Corp., please visit our website at www.adviral.com . Advanced Viral Research Corp., based in Yonkers, New York, is a biopharmaceutical firm dedicated to improving patients' lives by researching, developing and bringing to market new and effective therapies for viral and other diseases. Note: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by the Company. AVR118 (previously known as Product R) is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries. There is no assurance that the Company will be able to secure the financing necessary to continue and/or complete the clinical trials of AVR118 or satisfy certain other conditions relating to clinical trials including obtaining adequate insurance on terms acceptable to the Company or that if completed, clinical trials performed outside the United States will assist the Company in obtaining FDA or other regulatory approval. . The Company undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise. Contact: Ronnie Welch or Kelly Cinelli CWR & Partners 508/222-4802 SOURCE Advanced Viral Research Corp. -0- 02/25/2004 /CONTACT: Ronnie Welch or Kelly Cinelli, both of CWR & Partners, for Advanced Viral Research Corp., +1-508-222-4802/ /Company News On-Call: http://www.prnewswire.com/comp/903002.html/ /Web site: http://www.adviral.com/ (ADVR) CO: Advanced Viral Research Corp. ST: New York IN: MTC HEA BIO OTC SU: MT -- NYW083 -- 7370 02/25/2004 08:14 EST http://www.prnewswire.com E-mail this story Print this story Advanced Viral Resrh (BB) News Advanced Viral Research Corp. Announces the Resignation of Its Chief Financial Officer 20 April 2004, 07:20am ET, PR Newswire ADVR Appoints Dr. Carol Epstein as Acting Medical Director 8 April 2004, 07:30am ET, PR Newswire ADVR Abstract Selected for Presentation at the American Society of Clinical Oncology's (ASCO) 40th Annual Meeting 19 March 2004, 07:30am ET, PR Newswire More ADVR News |
| 3/19/04.
ADVR Abstract Selected for Presentation at the American Society of
Clinical Oncology's (ASCO) 40th Annual Meeting 19 March 2004, 07:30am ET YONKERS, N.Y., March 19 /PRNewswire-FirstCall/ -- Advanced Viral Research Corp. (BB:ADVR) announced today that an abstract on AVR118 has been selected for presentation at The American Society of Clinical Oncology's (ASCO) 40th Annual Meeting to be held in New Orleans, LA, June 5-8, 2004. The American Society of Clinical Oncology (ASCO) is the world's leading professional organization representing physicians who treat people with cancer. The ASCO Annual Meeting is the premiere educational event in the clinical oncology community. The meeting is targeted to U.S. and international physicians, academicians, and clinical researchers, as well as oncology fellows, nurses, social workers, physician assistants, and other healthcare professionals involved in multidisciplinary clinical cancer care. The 2003 Meeting in Chicago attracted 26,400 attendees from all over the world. Mentioned Last Change ADVR 0.11 0.01dollars or (8.33%) For further information regarding Advanced Viral Research Corp., please visit our website at http://www.adviral.com . Advanced Viral Research Corp., based in Yonkers, New York, is a biopharmaceutical firm dedicated to improving patients' lives by researching, developing and bringing to market new and effective therapies for viral and other diseases. ADVR's AVR118 represents a biopolymer that possesses novel immunomodulator activity. Note: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by the Company. AVR118 (Product R) is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries. There is no assurance that the Company will be able to secure the financing necessary to continue and/or complete the clinical trials of AVR118 or satisfy certain other conditions relating to clinical trials including obtaining adequate insurance on terms acceptable to the Company or that if completed, clinical trials performed outside the United States will assist the Company in obtaining FDA or other regulatory approval. The Company undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise. Contact: Ronnie Welch or Kelly Cinelli CWR & Partners 508/222-4802 SOURCE Advanced Viral Research Corp. -0- 03/19/2004 /CONTACT: Ronnie Welch or Kelly Cinelli, both of CWR & Partners, +1-508-222-4802, for Advanced Viral Research Corp./ /Company News On-Call: http://www.prnewswire.com/comp/903002.html / /Web site: http://www.adviral.com / (ADVR) CO: Advanced Viral Research Corp.; American Society of Clinical Oncology ST: New York IN: BIO HEA MTC OTC SU: TDS GS -- NYF013 -- 3666 03/19/2004 07:30 EST http://www.prnewswire.com E-mail this story Print this story Advanced Viral Resrh (BB) News Advanced Viral Research Corp. Announces the Resignation of Its Chief Financial Officer 20 April 2004, 07:20am ET, PR Newswire ADVR Appoints Dr. Carol Epstein as Acting Medical Director 8 April 2004, 07:30am ET, PR Newswire ADVR Abstract Selected for Presentation at the American Society of Clinical Oncology's (ASCO) 40th Annual Meeting 19 March 2004, 07:30am ET, PR Newswire More ADVR News - - - - - |
| Advanced
Viral Research Corp., based in Yonkers, New York, is a biopharmaceutical
firm dedicated to improving patients' lives by researching, developing
and bringing to market new and effective therapies for viral and other
diseases. WELL THE ABOVE IS TRUE EXCEPT FOR THE MOST IMPORTANT POINT, THE BRINGING TO MARKET POINT, AND IT SEEMS THEY CAN'T EVEN FINISH THE RESEARCH PART. JMHO |
| 4/8/04.
ADVR Appoints Dr. Carol Epstein as Acting Medical Director 8 April 2004, 07:30am ET YONKERS, N.Y., April 8 /PRNewswire-FirstCall/ -- Advanced Viral Research Corp. (BB:ADVR) announced today that Carol Epstein, MD has been appointed Acting Medical Director for the Company. Dr. Epstein is the co-founder of MediVector, Inc., a biopharmaceutical consulting firm with proprietary technology that can enable companies to cut the time and cost of drug development. "I am extremely pleased that Dr. Epstein has joined our team. Carol is known for her creative and strategic thinking," said Elma S. Hawkins, PhD, MBA, President and CEO of Advanced Viral Research Corp. "With her wealth of knowledge and expertise in clinical research and drug development, Carol is uniquely qualified to assist us in translating AVR118 into commercial realization. This marks the first time we have had someone with Dr. Epstein's level of expertise in clinical development at ADVR and demonstrates our commitment and focus in this area." Dr. Epstein started her career in the pharmaceutical industry in 1983 with Ayerst, a division of American Home Products. She then joined Immunex where she built the clinical group and was responsible for the successful clinical strategy that led to the approval of GM-CSF. Dr. Epstein later became Chief Medical Officer of Immunogen, and then co-founded BioLogics Services, Inc, a biopharmaceutical consulting firm. She has had extensive experience in oncology, immunology and autoimmune diseases, wound healing, cardiology, endocrinology and metabolism, and transplantation. Dr. Epstein graduated from MIT and Yale University School of Medicine. "I look forward to working with ADVR in developing and executing a comprehensive strategic plan for the clinical development of this very interesting and promising product," said Dr. Epstein. Mentioned Last Change ADVR 0.113 0.007dollars or (5.83%) Advanced Viral Research Corp., based in Yonkers, New York, is a biopharmaceutical firm dedicated to improving patients' lives by researching, developing and bringing to market new and effective therapies for viral and other diseases. ADVR's lead product, AVR118 (formerly known as Product R), represents a biopolymer that possesses novel immunomodulator activity. This peptide-nucleic acid, which to date has shown a very favorable safety profile, appears to stimulate the proinflammatory responses required to combat viral infections such as AIDS and human papilloma virus and to dampen aberrant autoimmune-type inflammatory responses, such as occur in patients with rheumatoid arthritis. AVR118 is in clinical trials in Israel for the treatment of cachexia (body wasting) in patients with AIDS. For further information regarding Advanced Viral Research Corp., please visit our website at www.adviral.com . Note: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by the Company. AVR118 (Product R) is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries. There is no assurance that the Company will be able to secure the financing necessary to continue and/or complete the clinical trials of AVR118 or satisfy certain other conditions relating to clinical trials including obtaining adequate insurance on terms acceptable to the Company or that if completed, clinical trials performed outside the United States will assist the Company in obtaining FDA or other regulatory approval. The Company undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise. Contact: Ronnie Welch or Kelly Cinelli CWR & Partners 508/222-4802 SOURCE Advanced Viral Research Corp. -0- 04/08/2004 /CONTACT: Ronnie Welch or Kelly Cinelli, both of CWR & Partners, +1-508-222-4802, for Advanced Viral Research Corp./ /Company News On-Call: http://www.prnewswire.com/comp/903002.html / /Web site: http://www.adviral.com / (ADVR) CO: Advanced Viral Research Corp. ST: New York IN: MTC BIO HEA OTC SU: PER WR -- NYTH011 -- 6818 04/08/2004 07:30 EDT http://www.prnewswire.com E-mail this story Print this story Advanced Viral Resrh (BB) News Advanced Viral Research Corp. Announces the Resignation of Its Chief Financial Officer 20 April 2004, 07:20am ET, PR Newswire ADVR Appoints Dr. Carol Epstein as Acting Medical Director 8 April 2004, 07:30am ET, PR Newswire ADVR Abstract Selected for Presentation at the American Society of Clinical Oncology's (ASCO) 40th Annual Meeting 19 March 2004, 07:30am ET, PR Newswire More ADVR News |
| 4/20/04.
Advanced Viral Research Corp. Announces the Resignation of Its Chief
Financial Officer 20 April 2004, 07:20am ET YONKERS, N.Y., April 20 /PRNewswire-FirstCall/ -- Advanced Viral Research Corp. (BB:ADVR) announced today that Mr. Alan Gallantar has resigned as Chief Financial Officer and Treasurer effective April 19th, 2004. Mr. Gallantar informed the Company that he is leaving ADVR to attend to a personal matter. Mr. Martin Bookman, who has been with ADVR as Assistant Controller since March of 2001, has been appointed Acting Chief Financial Officer. Advanced Viral Research Corp., based in Yonkers, New York, is a biopharmaceutical firm dedicated to improving patients' lives by researching, developing and bringing to market new and effective therapies for viral and other diseases. ADVR's lead product, AVR118 (formerly known as Product R), represents a biopolymer that possesses novel immunomodulator activity. This peptide-nucleic acid complex, which to date has shown a very favorable safety profile, appears to stimulate the proinflammatory responses required to combat viral infections such as AIDS and human papilloma virus and to dampen aberrant autoimmune-type inflammatory responses, such as occur in patients with rheumatoid arthritis. AVR118 is in clinical trials in Israel for the treatment of cachexia (body wasting) in patients with AIDS. Mentioned Last Change ADVR 0.113 0.007dollars or (5.83%) For further information regarding Advanced Viral Research Corp., please visit our website at www.adviral.com . Note: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by the Company. AVR118 (Product R) is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries. There is no assurance that the Company will be able to secure the financing necessary to continue and/or complete the clinical trials of AVR118 or satisfy certain other conditions relating to clinical trials including obtaining adequate insurance on terms acceptable to the Company or that if completed, clinical trials performed outside the United States will assist the Company in obtaining FDA or other regulatory approval. The Company undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise. Contact: Ronnie Welch or Kelly Cinelli CWR & Partners 508/222-4802 SOURCE Advanced Viral Research Corp. -0- 04/20/2004 /CONTACT: Ronnie Welch or Kelly Cinelli, both of CWR & Partners, +1-508-222-4802, for Advanced Viral Research Corp. / /Company News On-Call: http://www.prnewswire.com/comp/903002.html / /Web site: http://www.adviral.com / (ADVR) CO: Advanced Viral Research Corp.; ADVR ST: New York IN: HEA MTC BIO OTC SU: PER KB -- NYTU080 -- 6779 04/20/2004 07:20 EDT http://www.prnewswire.com E-mail this story Print this story Advanced Viral Resrh (BB) News Advanced Viral Research Corp. Announces the Resignation of Its Chief Financial Officer 20 April 2004, 07:20am ET, PR Newswire ADVR Appoints Dr. Carol Epstein as Acting Medical Director 8 April 2004, 07:30am ET, PR Newswire ADVR Abstract Selected for Presentation at the American Society of Clinical Oncology's (ASCO) 40th Annual Meeting 19 March 2004, 07:30am ET, PR Newswire More ADVR News |
bring
back (im gonna puke) bregmenn
|
||
| anna...
here is some history on the ex-CFO. Ask anyone here if he met his goals,
especially 2-6. But he did loan some big bucks to get rid of the
founders, Breg & Fried! EXHIBIT A-1 ----------- Corporate Performance Goals --------------------------- The corporate objectives, the attainment of which 50% of the discretionary bonus payable to the Employee will depend, include the following: 1. Approval of one or more IND's by the United States Food and Drug Administration; 2. Increased values for shareholders reflected by long term stock price appreciation; 3. Attainment of listing on NASDAQ SmallCap Market and, subsequently, on the NASDAQ National Market; 4. The execution of material license agreements with attendant royalty streams payable to the Corporation; 5. Successful completion of corporate finance transactions resulting in the infusion of equity, quasi equity and/or long term debt into the Corporation (not including so called "death spiral" transactions); 6. Joint venture transactions with major pharmaceutical companies; 17 EXHIBIT A-2 ----------- Individual Performance Goals1 ----------------------------- The individual objectives, the attainment of which 50% of the discretionary bonus payable to the Employee will depend, include the following: 1. Establish and maintain policies for effective investor communications; 2. Establish and maintain financial controls, reporting systems and accounting policies and provide timely and accurate operating information to management and regulatory agencies; 3. Move the accounting, legal and financial reporting functions to New York headquarters; 4. Prepare budgets for the Company; 5. Establish and maintain an approval process for growth and development plans; 6. Analyze results of operations versus budget and prior year results of operations; 7. Make recommendations to the CEO and Board of Directors with respect to operating efficiencies; 8. Develop and supervise staff; 9. Develop and maintain a corporate culture and mission statement; 10. Develop and maintain investor communications procedures; 11. Develop and maintain employee benefit plans, including a 401(k) plan; 12. Discuss, develop and maintain a business plan strategy for the Company; 13. Develop and maintain corporate governance policies to expand the breadth of the Board of Directors and Advisory Boards; 14. Develop and maintain risk management policies for the Company; 15. Develop intangible property policies for the Company; 16. Maintain an ongoing relationship between the Company and NASDAQ and market makers; 17. Develop a strategy to move the Company from OTC Bulletin Board to NASDAQ SmallCap listing. |
| yanks.....MM's
are holding ADVR until they accumulate enough shares for the BIG run on
significant news. The MM's are very smart. They know that no more
"quality investors" are coming since the Dickie boys ponied up
$12MM. They have to accumulate and/or cover because next time ADVR runs,
it may not come back. The PPS might drift down to .08 but I don't care,
I've been here for almost 10 years and have lot's of patience. Life goes
on and time goes by. Many opportunities were here to make money on ups
and downs and there will be more, especially a BIG one. The best way to
handle ADVR is not to microwatch the PPS but to diversify on other
stocks until the BIG day arrives and it WILL come! |
| anna.....Gallantar
loaned $200k to the company so they could dump Breg and Fried ASAP. He got his money back when Harborview(Larry Pomerantz-who Telit trashed earlier) invested some more of his and his group's money in ADVR. Makes you wonder how a CFO who had cash, never invested a single penny into the company that paid him handsomely for 3 years + 18 months? Not to mention our illustrious ex-CEO, Dr. H! The Agreements, attached hereto as Exhibits 10.1, 10.2 and 10.3, provide for, among other things, the payment of $150,000 in one lump sum to each of Messrs. Bregman and Friedland, and the payment of $2,500 to Mr. Silver, in consideration for their resignation as directors and/or officers of the Registrant and its subsidiary. In connection with the Agreements, the Registrant obtained a loan in the amount of $200,000 from its Chief Financial Officer, Alan Gallantar, as evidenced by a Demand Promissory Note made by the Registrant in favor of Mr. Gallantar attached hereto as Exhibit 10.4 (the "Note"). Pursuant to the terms of the Note, the Registrant was obligated to repay the promissory note upon the receipt by the Registrant of proceeds upon the consummation of new financing. The Note was satisfied by the Registrant upon the receipt by the Registrant of proceeds in connection with a Securities Purchase Agreement dated December 17, 2001 between the Registrant and Harbor View Group, Inc. (Voluntary Disclosure: Position- Long) - - - - - |
| "MM's
walking it down on the BS CFO news release." Or maybe folks are simply tired of ADVR's never-ending series of failures, and are just selling?? Why is it always the MMs fault that a company's stock has a declining PPS? |
| Bernie,
no one is blaming the MM's...they have a job to do.....get as much stock
as they can to provide liquidity to the market. It is no secret when a company puts out what is perceived as bad news the MM's start pulling the Bids as some selling begins. It usually ends in a "hammer" bottom and the price quickly bounces back. The drop has begun as you can see on today's daily chart and will probably bounce around .08 which would be a tremendous buying opportunity.....time to put those HLSH profits back to work! LOL! |
| "The
drop has begun as you can see on today's daily chart and will probably
bounce around .08 which would be a tremendous buying
opportunity.....time to put those HLSH profits back to work! LOL! Seriously, ADVR has never been in better shape. They got the MONEY. They now have the management. And.....they have the DRUG!!!" --------------------- You got it Babe! LIA |
| Hi
Anna, Not sure why the drop....possibly because there is nothing new to report in a positive venue. I don't think the loss of ADVR's CFO is that big of a deal (I really don't)...heck, I don't even think the stock dropped at all when Dr. Hirschman resigned as CEO and Director. It's possible there are "forces" out there playing on this aspect, but I don't think as the MM's do, so I don't know for sure. BTW: I am a bit jealous of your entry price. I came in at $.75 and bought again at $.50 (those were the good old days when a chipmunk could pump ADVR and a lot of us "believed"). ADVR keeps spinning its wheels in different directions, and I've grown accustomed to its face. I'm about ready for an ADVR facelift!! Cheers! Sue |
| Excellent
post....thanks for pointing this out. The up side of AG leaving is a reduction in payroll. He was grossly overpaid for ADVR's position in the bio market . Look at the money we have saved. When SH's contract is up there should be some further savings. (Voluntary Disclosure: Position- Long) |
| SUE,
The past CEO made over 500K ! The new CEO much less. Advanced Viral should show a profit just on that lol Well if the company cut some corners and move the drug along, we both will be happy no matter where we bought. We do not hold a lot of shares. Admire your patience ! have a good evening anna |
| LOL...Anna,
believe it or not, the company is STILL PAYING the former CEO THE SAME
SALARY plus perks (even after his resignation - his title is now Chief
Scientist, that is until this December) AND is ALSO paying THE NEW CEO
HER SALARY plus 40 million shares in options. You really NEED to read
the last SEC report (10-K). Read the employment contracts. The company
really DOES take care of its own!!!....LOL. Even though the lowly
shareholders are "declared" to be the backbone of the company. Good night; may ADVR have a better day tomorrow! |
| Ana
The Co has finally put itself lin a postion to move fofward wth the new
CEO and acting medical director. While the CEO is still familurizing
herself with all hat went on for the last 15 years so that she may be
able to make the info usefull, the Co must still proceed sswith these
qualified persons. In the long run, the stockolders will gain from this
short period. |
| "TB
Case Found at Yonkers High; 100 to Be Tested" Associated Press (04.20.04) Westchester County Health Department officials are suggesting skin tests for about 100 students and staff members at Yonkers High School after a person there was diagnosed with TB. Those who shared a classroom with the infected person or had other significant contact should undergo the tests, which will be offered at the school or can be taken in a doctor's office, said Health Commissioner Joshua Lipsman. The county usually sees 60-70 TB cases annually. ***************************************************** |
click
to retrieve filing
